MedWatch

Novo’s younger sibling has growing pains

Novo Nordisk’s lesser-known haemophilia division is moving into the limelight. There is a much bigger patient population waiting that we have not even begun to focus on, the VP in charge of the division says. But Novo’s younger sibling will be facing some of the big boys in the schoolyard.

Foto: Novo Nordisk PR

They are gearing up for something big in Novo Nordisk’s haemophilia division. But to the general public the disease haemophilia is not normally what you would associate the Danish pharmaceutical giant with.

A database search of Danish newspaper articles reveals that there were 1,006 articles containing the words ‘diabetes’ and ‘Novo Nordisk’ published in the last five years, while the word ‘haemophilia’ only appeared in conjunction with the company’s name in 54 instances.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Eli Lilly får forlomme til fedmehåb hos FDA

Med en fast track status får medicinalselskabet Eli Lilly sænket behandlingstiden for sin registreringsansøgning hos FDA af lægemiddelhåbet Tirzepatid til omtrent seks måneder fra de normale ca. 10 måneder.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier